title: Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).
abstract: OBJECTIVE
  Zibotentan (ZD4054) is a specific endothelin A receptor antagonist in clinical development for the treatment of hormone-resistant prostate cancer (HRPC). In a Phase II trial in patients with pain-free or mildly symptomatic metastatic HRPC, zibotentan was well tolerated with a promising signal for prolonged overall survival compared with placebo. As part of this trial, the impact of zibotentan compared with placebo on health-related quality of life (HRQoL) was assessed.
  
  
  METHODS
  Patients were randomized to receive once-daily oral zibotentan 10 or 15 mg, or matching placebo. Patients were allocated to one of two questionnaires; the Functional Assessment of Cancer Therapy-Prostate (FACT-P) or the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), supplemented by PR25, specific for prostate cancer. Questionnaires were completed at baseline and every 4 weeks until disease progression when study treatment was discontinued.
  
  
  RESULTS
  Compliance with questionnaire completion was >90% (286 of 312 patients) of the intention-to-treat population at baseline. Of baseline completers who were available for assessment (i.e., had not clinically progressed), 89% (164 of 184) and 83% (73 of 88) completed questionnaires at 12 and 24 weeks, respectively. HRQoL scores from both questionnaires were high at baseline and remained high throughout the study, with scores being similar in the zibotentan and placebo groups. However, some floor and ceiling effects were seen in the EORTC QLQ-C30 questionnaire.
  
  
  CONCLUSIONS
  High-baseline HRQoL scores were maintained throughout treatment with zibotentan. The FACT-P instrument was selected to further assess the impact of zibotentan on HRQoL in the Phase III clinical trial program.
authors.affiliation: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Dawson
authors.affiliation: University College Hospital, London, UK.
authors.forename: Heather
authors.initials: H
authors.lastname: Payne
authors.affiliation: AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TF, UK. clare.battersby@astrazeneca.com.
authors.forename: Clare
authors.initials: C
authors.lastname: Battersby
authors.affiliation: AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, SK10 4TF, UK.
authors.forename: Maria
authors.initials: M
authors.lastname: Taboada
authors.affiliation: School of Cancer Sciences, University of Birmingham, Birmingham, UK.
authors.forename: Nick
authors.initials: N
authors.lastname: James
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D019008:Drug Resistance, Neoplasm; D065130:Endothelin A Receptor Antagonists; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000523:psychology*; D011759:Pyrrolidines / Q000627:therapeutic use*; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; D065130:Endothelin A Receptor Antagonists; D011759:Pyrrolidines; C511404:ZD4054
references.citation: Qual Life Res. 1996 Apr;5(2):212-22
references.pmid: 8998490
references.citation: Value Health. 2009 Jan-Feb;12(1):124-9
references.pmid: 18647260
references.citation: Anticancer Drugs. 2009 Feb;20(2):83-8
references.pmid: 19065106
references.citation: Qual Life Res. 2007 May;16(4):571-5
references.pmid: 17294287
references.citation: J Clin Oncol. 1999 Sep;17(9):2932-40
references.pmid: 10561373
references.citation: Eur Urol. 2009 May;55(5):1112-23
references.pmid: 19042080
references.citation: J Clin Oncol. 1993 Mar;11(3):570-9
references.pmid: 8445433
references.citation: J Clin Oncol. 1998 Jan;16(1):139-44
references.pmid: 9440735
references.citation: BJU Int. 2009 Nov;104(10):1423-5
references.pmid: 19624592
references.citation: Clin Cancer Res. 2008 May 1;14(9):2763-7
references.pmid: 18451243
references.citation: Health Qual Life Outcomes. 2003 Nov 21;1:69
references.pmid: 14633279
references.citation: Urology. 1997 Dec;50(6):920-8
references.pmid: 9426724
references.citation: J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
references.pmid: 8433390